Tricyclo Ring System Having The Seven-membered Hetero Ring A One Of The Cyclos Patents (Class 514/217)
  • Patent number: 10959974
    Abstract: Provided in the present invention are ingenol compounds and a use thereof in preparing an anti-HIV latency drug. In particular, provided in the present invention is a use of ingenol compounds and pharmaceutically acceptable salts thereof for preparing a drug for: (a) intervening with HIV viral latency; (b) activating an HIV virus that has been integrated into mammalian genomes; and/or (c) inducing the expression of the dormant HIV provirus in infected cells. The compounds of the present invention may also be used in combination with antiretroviral drugs to accelerate the removal of latent viral reservoirs.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: March 30, 2021
    Assignee: SHANGHAI XIN HAO BIOLOGICAL TECHNOLOGY COMPANY
    Inventors: Longfei Zhang, Pengfei Wang, Zhongjun Ma, Huanzhang Zhu
  • Patent number: 10918608
    Abstract: The present disclosure relates to the use of cannabidiol (CBD) for the treatment of Tuberous Sclerosis Complex (TSC). In particular the TSC is treatment resistant and is characterised by generalised seizures or focal seizures with impairment. The disclosure further relates to the use of CBD in combination with one or more anti-epileptic drugs (AEDs).
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: February 16, 2021
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Elizabeth Thiele
  • Patent number: 10888568
    Abstract: The present invention relates to use of antipsychotic phenothiazine derivative for treatment of cancer. The invention also provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating a cancer, and/or preventing or delaying cancer recurrence based on trifluoperazine. The invention further provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating cancer based on thioridazine and its enantiomers. Additionally, the invention provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating KRAS mutant NSCLC comprising thioridazine.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: January 12, 2021
    Assignee: National Yang Ming University
    Inventors: Chi-Ying Huang, Jane Hsiao, Pan-Chyr Yang, Meng-Hua Lee
  • Patent number: 10813999
    Abstract: The invention provides liquid or semi-solid pharmaceutical compositions for topical administration comprising a semifluorinated alkane. The compositions are useful for the delivery of active ingredients into the deep layers of the skin or skin appendages. Various active ingredients may be incorporated, such as immunosuppressants, antiinfectives, antifungal agents, antiinflammatory agents, and retinoids.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: October 27, 2020
    Assignee: NOVALIQ GMBH
    Inventors: Bernhard Gunther, Bastian Theisinger, Sonja Theisinger, Dieter Scherer
  • Patent number: 10815197
    Abstract: The present invention discloses an N-sulfonyl benzamide derivative with a heterocyclic substituent, and a preparation method therefor and a pharmaceutical application thereof. More specifically, the invention discloses a compound represented by formula (II) or a pharmaceutically acceptable salt, stereoisomer, solvent compound, or prodrug thereof, and a preparation method therefor and an application thereof. Refer to the specification for definitions of each group in the formula.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 27, 2020
    Assignees: SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD., YANGTZE RIVER PHARMACEUTICAL GROUP CO., LTD.
    Inventors: Jiong Lan, Fusheng Zhou, Jinzhu Zhao, Dong Huang, Jing Xie, Yi Hu, Qiang Lv
  • Patent number: 10736859
    Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: August 11, 2020
    Assignee: Tonix Pharma Holdings Limited
    Inventors: Marino Nebuloni, Patrizia Colombo
  • Patent number: 10709671
    Abstract: The present invention relates to the use of cannabidiol (CBD) in the treatment of focal seizures. In one embodiment the patients suffering from focal seizures are children and young adults. CBD appears particularly effective in reducing focal seizures in patients suffering with etiologies that include: Lennox-Gastaut Syndrome; Tuberous Sclerosis Complex; Dravet Syndrome; CDKL5; Neuronal ceroid lipofuscinoses (NCL); febrile infection related epilepsy syndrome (FIRES); Aicardi syndrome and brain abnormalities in comparison to other seizure types. Significantly CBD additionally is very effective in the reduction of a sub-type of focal seizures, focal seizures with impairment.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: July 14, 2020
    Assignee: GW Research Limited
    Inventors: Geoffrey Guy, Stephen Wright, Orrin Devinsky
  • Patent number: 10662146
    Abstract: Disclosed herein are pharmaceutical compositions with fencamfamine or fencamfamine related prodrug derivatives. The pharmaceutical compositions are for targeted therapeutic applications including, but not limited to, treating cancer-related fatigue, apathy in Alzheimer's Disease, major depression, and attention deficit-hyperactivity disorder. Also disclosed are methods of synthesizing the pharmaceutical compositions with fencamfamine or fencamfamine related prodrug derivatives.
    Type: Grant
    Filed: September 13, 2016
    Date of Patent: May 26, 2020
    Assignee: PRAXIS BIORESEARCH, LLC
    Inventors: Sandeep Patil, Ron Bihovsky, Steven A. Smith, Yuhua Ji, Valentino Stella, Daniel D. Long, Daniel Marquess
  • Patent number: 10653662
    Abstract: Methods of preventing early awakenings, and improving sleep efficiency in hours 7 and 8 of a period of sleep, by administration of low doses of doxepin (e.g., 1-6 mg).
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: May 19, 2020
    Assignees: Currax Pharmaceuticals LLC, ProCom One, Inc.
    Inventors: Roberta L. Rogowski, Susan E. Dubé, Philip Jochelson, Neil B. Kavey
  • Patent number: 10640490
    Abstract: The present invention provides a diaminopyrimidine derivative or its pharmaceutically acceptable salt, a process for the preparation thereof, a pharmaceutical composition comprising the same, and a use thereof. The diaminopyrimidine derivative or its pharmaceutically acceptable salt functions as a 5-HT4 receptor agonist, and therefore can be usefully applied for preventing or treating dysfunction in gastrointestinal motility, one of the gastrointestinal diseases, such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, or diabetic gastric atony.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: May 5, 2020
    Assignee: Yuhan Corporation
    Inventors: Hyun-Joo Lee, Dong-Hoon Kim, Tae-Kyun Kim, Young-Ae Yoon, Jae-Young Sim, Myung-Hun Cha, Eun-Jung Jung, Kyoung-Kyu Ahn, Tai-Au Lee
  • Patent number: 10583150
    Abstract: The present invention relates to a pharmaceutical composition for treating macular degeneration, and more particularly to a pharmaceutical composition for treating macular degeneration, which comprises an inhibitor of mTOR gene expression. The pharmaceutical composition according to the present invention can effectively treat age-related macular degeneration, a representative retinal disease that causes blindness in adults.
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: March 10, 2020
    Assignee: CuroGene Life Sciences Co., Ltd.
    Inventors: Young-Ill Lee, Steven Hyun Seung Lee, Tae Kwann Park
  • Patent number: 10518112
    Abstract: Method for ameliorating secondary pulmonary hypertension in a patient including determining a pulmonary vascular resistance (PVR) of the patient suffering from secondary pulmonary hypertension; assessing a change in the PVR in response to a selection treatment; and treating the patient with a pulmonary artery manipulation device to provide pulmonary artery denervation if the patient is determined to suffer from fixed PH, thereby ameliorating the secondary pulmonary hypertension of the patient.
    Type: Grant
    Filed: June 16, 2015
    Date of Patent: December 31, 2019
    Assignee: SONIVIE LTD.
    Inventor: Rotem Gilad
  • Patent number: 10420318
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: September 24, 2019
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 10421779
    Abstract: The present invention relates to a carbazole compound having anti-virus activity, and more particularly, to a novel compound selected from the group of consisting of a carbazole compound which shows excellent anti-proliferative efficacy against hepatitis C virus (HCV), a pharmaceutically acceptable salt thereof, a hydrate thereof, and an isomer thereof; an anti-virus pharmaceutical composition including the novel compound as an active ingredient; a pharmaceutical composition for preventing or treating liver diseases caused by hepatitis C virus; and a method of preparing the novel compound.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: September 24, 2019
    Assignees: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY, POSTECH ACADEMY-INDUSTRY FOUNDATION
    Inventors: Gyo Chang Keum, Eunice Eun Kyeong Kim, Sung Key Jang, Hee Sun Kim, Ae Nim Pae, Hua Li, Jin Hyeong Park, Jin Sook Kwak
  • Patent number: 10406189
    Abstract: Compositions and methods for the treatment and prevention of at least one of a sign and a symptom associated with an eye disease are disclosed. Preferred compositions could comprise a liquid formulation including Cineraria maritima and at least one of a nonsteroidal anti-inflammatory drug, a carnosine, and a cannabinoid.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: September 10, 2019
    Inventor: Leonidas A. Johnson
  • Patent number: 10376523
    Abstract: An aqueous composition having an excellent antiseptic effect is provided. An aqueous composition containing: a compound represented by Formula (1), a salt thereof, or a solvate of the compound or the salt thereof, where X represents a halogen atom, and a quaternary ammonium surfactant. A method for producing an aqueous composition with an antiseptic effect, by incorporating a compound represented by Formula (1), a salt thereof, or a solvate of the compound or the salt thereof and a quaternary ammonium surfactant into the aqueous composition.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: August 13, 2019
    Assignee: KOWA COMPANY, LTD.
    Inventor: Shin Sugimoto
  • Patent number: 10258498
    Abstract: The invention provides 1,4-dihydropyridine derivatives of formula (I) wherein R1 is optionally substituted C6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; R2 and R3 are independently hydrogen or C1-6alkyl group; R4 and R5 are independently hydrogen, C1-6alkyl group optionally substituted with amino, mono- or di(C1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 N, O, S heteroatoms and optionally substituted with C1-6alkyl group or C1-6 alkoxy group; R6 is C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkylC1-6alkyl or arylC1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder medi
    Type: Grant
    Filed: November 22, 2012
    Date of Patent: April 16, 2019
    Assignee: Richter Gedeon NYRT.
    Inventors: Ferenc Fülöp, László Vigh, Zsolt Török, Botond Penke, Ibolya Horváth, Gábor Balogh, Sándor Bernáth, Ákos Hunya
  • Patent number: 10239861
    Abstract: The invention relates to compounds of formula (I) and salts thereof: wherein R1-R3 have any of the values defined in the specification. The compounds and salts are useful for treating PCAF mediated disorders and/or GCN5 mediated disorders. The invention also provides pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, as well as and methods of using said compounds, salts, or compositions in the treatment of various disorders.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: March 26, 2019
    Assignees: GENETECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Daniel J. Burdick, Alexandre Cote, Martin Duplessis, Christopher G. Nasveschuk, Alexander M. Taylor
  • Patent number: 10239841
    Abstract: The invention relates to a production method of pyrazole derivative (6) by reacting compound (5) with an oxidant. wherein R1, R2, R3, X1, X2 and Z1 are as defined herein.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: March 26, 2019
    Assignee: AGC Inc.
    Inventors: Yuichiro Ishibashi, Yosuke Ochi, Noriaki Miyake, Yusuke Yamazaki, Shota Shimizu
  • Patent number: 10149838
    Abstract: The present invention relates to use of novel securinine and norsecurine analogs to bind and/or inhibit myeloperoxidase activity.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: December 11, 2018
    Inventors: Mahesh K. Gundluru, Mukesh Agarwal, Zhiqing Xia, Goutam Karan, David Wald
  • Patent number: 10085414
    Abstract: A methylphenidate, particularly including dextro-threo-methylphenidate, is administered to a subject to treat a speech, gait or limb impairment secondary to a genetically acquired pre-frontal cortex processing disease or disorder, particularly including multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and Fragile-X syndrome.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: October 2, 2018
    Assignee: GILROSE PHARMACEUTICALS, LLC
    Inventors: Bruce Roseman, Gilla Kaplan
  • Patent number: 9937186
    Abstract: A genus of arylsulfonamide derivatives of aminocycloalkanols is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequence, exhibit anti-proliferative effects. They are useful in the treatment of a variety of disorders, including as a monotherapy in cancer treatment, or used in combination with other drugs to restore sensitivity to chemotherapy where resistance has developed.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: April 10, 2018
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Michael Ohlmeyer, David Kastrinsky
  • Patent number: 9937180
    Abstract: Tricyclic chemical modulators of protein phosphatase 2A are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: April 10, 2018
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Michael Ohlmeyer, David Kastrinsky
  • Patent number: 9913833
    Abstract: Methods of treating developmental disorders by administering a pharmaceutical composition of pipradrol or a pharmaceutically acceptable salt thereof are provided. The methods may be used to treat conditions such as epilepsy, Landau-Kleffner Syndrome, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
    Type: Grant
    Filed: April 21, 2017
    Date of Patent: March 13, 2018
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Patent number: 9895353
    Abstract: Described is the use of L-tryptophan for treating a subject with parasomnia and associated methods of treating a subject with parasomnia. Optionally, the subject may be a child or adolescent between about 3 years of age and 18 years of age. The methods and uses described herein are useful for treating parasomnia in a subject exhibiting sleep walking, sleeptalking, confusional arousals, nightmares, night terrors, rhythmic movement disorder, sleep related eating disorder and/or bruxism. Optionally, subjects are treated with a dose L-tryptophan of about between 700 mg and 5 g per day.
    Type: Grant
    Filed: September 10, 2014
    Date of Patent: February 20, 2018
    Assignee: Zzeemag Inc.
    Inventors: Colin Shapiro, Louis Van Zyl
  • Patent number: 9855277
    Abstract: The use of 5H-dibenz/b,f/azepine-5-carboxamide derivatives for treating fibromyalgia. Useful 5H-dibenz/b,f/azepine-5-carboxamide derivatives include compounds of the formula (I): where R1 is hydrogen, alkyl, halogenalkyl, aralkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, or pyridyl; the term alkyl means a straight or branched hydrocarbon chain containing from 1 to 18 carbon atoms; the term halogen means fluorine, chlorine, bromine or iodine; the term cycloalkyl means an alicyclic saturated group with 3 to 6 carbon atoms; and the term aryl means an unsubstituted phenyl group or phenyl substituted by alkoxy, halogen or nitro group.
    Type: Grant
    Filed: July 27, 2009
    Date of Patent: January 2, 2018
    Assignee: BIAL—PORTELA & CA, S.A.
    Inventor: Patricio Manuel Viera Araújo Soares Da Silva
  • Patent number: 9801847
    Abstract: The invention relates to use of the cis-(Z) isomer or isomeric mixtures containing specified ratios of the cis-(Z) and trans-(E) isomers of doxepin, metabolites of doxepin, pharmaceutically-acceptable salts of doxepin and prodrugs of the same; compositions containing the same, for the treatment of sleep disorders.
    Type: Grant
    Filed: October 10, 2016
    Date of Patent: October 31, 2017
    Assignees: Pernix Sleep, Inc., ProCom One, Inc.
    Inventors: Susan E. Dubé, Neil B. Kavey
  • Patent number: 9796720
    Abstract: Novel non-steroidal compounds are provided which are useful in treating diseases or disorders associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-?B activity, including metabolic and inflammatory and immune diseases or disorders, having the structure of formula (I): an enantiomer, diastereomer, or tautomer thereof, or a prodrug ester thereof, or a pharmaceutically-acceptable salt thereof, in which the variables are as defined in the specification.
    Type: Grant
    Filed: August 21, 2014
    Date of Patent: October 24, 2017
    Assignee: Bristol-Myers Squibb Company
    Inventors: Michael G. Yang, Zili Xiao, David S. Weinstein
  • Patent number: 9763954
    Abstract: New applications of eslicarbazepine and eslicarbazepine acetate in the treatment of intractable conditions.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: September 19, 2017
    Assignee: BIAL—PORTELA & CA, S.A.
    Inventor: Patricio Manuel Vieira Araújo Soares Da Silva
  • Patent number: 9738631
    Abstract: The invention relates to the compounds of formula I and formula IA or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I and formula IA; and methods for treating or preventing neurological diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of epilepsy, bipolar disorder, trigeminal neuralgia, attention-deficit hyperactivity disorder (ADHD), schizophrenia, neuropathic pain, seizures, bipolar disorder, mania, phantom limb syndrome, complex regional pain syndrome, paroxysmal extreme pain disorder, neuromyotonia, intermittent explosive disorder, borderline personality disorder, Myotonia congenita and post-traumatic stress disorder.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: August 22, 2017
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Patent number: 9695144
    Abstract: The present disclosure provides dibenzazepine derivatives having Formula I or I(A): and the pharmaceutically acceptable salts and solvates thereof, wherein R3a, R3b, R6, V1, V2, Z1, Z2, Z3, and G are defined as set forth in the specification. The present disclosure is also directed to the use of the compounds of Formula I or I(A), and the pharmaceutically acceptable salts or solvates thereof, to treat a disorder responsive to the blockade of one or more sodium channels. In one embodiment, the compounds of the present disclosure are useful for treating pain.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: July 4, 2017
    Assignee: Purdue Pharma L.P.
    Inventors: Stephen M. Lynch, Laykea Tafesse
  • Patent number: 9643929
    Abstract: A process for preparing (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide or (R)-(?)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a hydride source is disclosed. The catalyst is prepared from a combination of [RuX2(L)]2 wherein X is chlorine, bromine or iodine, and L is an aryl or aryl-aliphatic ligand, with a ligand of formula (A) or formula (B): wherein R1 is chosen from C1-6 alkoxy and C1-6 alkyl, n is a number from 0 to 5, and when n is a number from 2 to 5, R1 can be the same or different, and R2 is alkyl, substituted alkyl, aryl, substituted aryl, alkaryl or substituted alkaryl. The hydride source is either NR3R4R5 and formic acid, [R3R4R5NH][OOCH] and optionally formic acid, or [M][OOCH]x and formic acid, wherein R3, R4 and R5 are C1-6 alkyl, M is an alkali metal or alkaline earth metal and x is 1 or 2. A pH from 6.5 to 8 is maintained during the process.
    Type: Grant
    Filed: November 18, 2015
    Date of Patent: May 9, 2017
    Assignee: BIAL—PORTELA & CA, S.A.
    Inventors: David Alexander Learmonth, Gabriela Alexandra Grasa, Antonio Zanotti-Gerosa
  • Patent number: 9567291
    Abstract: This disclosure relates to N-(4-(bis(4-(dimethylamino)phenyl)methylene)-8 -(dimethylamino)naphthalen-1(4H)-ylidene)-N-methylmethanaminium, derivatives, and uses related thereto. In certain embodiments, the disclosure relates to compounds of formula I. In certain embodiments, the disclosure relates to methods of treating or preventing Nox related diseases and conditions comprising administering an effective amount of compounds disclosed herein to a subject in need thereof. In certain embodiments, the Nox related disease or condition is cancer.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: February 14, 2017
    Assignee: Emory University
    Inventor: Jack Arbiser
  • Patent number: 9540358
    Abstract: Tricyclic chemical modulators of FOXO transcription factor proteins are disclosed. The compounds are useful to treat cancer, age-onset proteotoxicity, stress-induced depression, inflammation, and acne.
    Type: Grant
    Filed: August 16, 2012
    Date of Patent: January 10, 2017
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Michael Ohlmeyer, Goutham Narla, Neil Dhawan, David Kastrinsky
  • Patent number: 9494572
    Abstract: The present invention relates to anti-cancer therapeutics. In certain aspects, cancers are treated with a combination of an anti-EGFR agent and an agent that increases the activity of the KLF6 tumor suppressor gene and/or an agent that increases activity of the FOXO1 tumor suppressor gene. In a preferred aspect, the anti-EGFR agent erlotinib a tricyclic agent compound, are used in combination to treat non-small cell lung cancer in a patient with primary or acquired drug resistance to erlotinib, and wherein the tricyclic agent is administered in an amount that does not lead to a substantial central nervous system effect. In additional aspects, the invention relates to compositions and kits useful for treating cancers, methods for screening for compounds that enhance the activity of anti-EGFR agent, and methods for determining whether a patient will respond to anti-EGFR therapy.
    Type: Grant
    Filed: February 6, 2015
    Date of Patent: November 15, 2016
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Goutham Narla, Michael Ohlmeyer, Matthew David Galsky, Suzanna Katz
  • Patent number: 9469632
    Abstract: A TARP ?8 dependant AMPA receptor antagonist of the formula: wherein X is CH or N; A is and R1 is as defined herein; its pharmaceutically acceptable salts, uses, and methods for its preparation are described.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: October 18, 2016
    Assignee: Eli Lilly and Company
    Inventors: Kevin Matthew Gardinier, Douglas Linn Gernert, Patric James Hahn, Sean Patrick Hollinshead, Albert Khilevich, Daniel Ray Mayhugh, Paul Leslie Ornstein, Warren Jaye Porter, Jon Kevin Reel, Jeffrey Michael Schkeryantz, Patrick Gianpietro Spinazze, Freddie Craig Stevens, Jeffrey Michael Witkin
  • Patent number: 9394327
    Abstract: The uses of antifreeze proteins (AFPs), including polypeptides, peptides, fragments of AFPs, and mimicries of AFPs, as highly efficient additives for crystal growth control are provided. AFPs are demonstrated to efficiently inhibit the nucleation of commercially and pharmaceutically important compounds (e.g., nucleosides, sugars, salts), increase the supersaturation of their solutions, modify their crystal habits, and result in novel morphologies.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: July 19, 2016
    Assignee: The Trustees of California State University
    Inventors: Xin Wen, Sen Wang
  • Patent number: 9351968
    Abstract: Methods of treating developmental disorders by administering a pharmaceutical composition of pipradrol or a pharmaceutically acceptable salt thereof are provided. The methods may be used to treat conditions such as epilepsy, Landau-Kleffner Syndrome, Lennox-Gastaut syndrome (LGS) and Dravet syndrome.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: May 31, 2016
    Assignee: OVID THERAPEUTICS INC
    Inventor: Matthew During
  • Patent number: 9346760
    Abstract: The present invention provides a novel process for the preparation of substituted optically pure (S)-(+)- or (R)-(?)-10-hydroxy-dihydrodibenz[b,f]azepines or derivatives thereof, starting from 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepines using boronate esters or their derivatives. The present invention also provides use of thus prepared (S)-(+)- or (R)-(?)-10-hydroxy-dihydrodibenz[b,f]azepines for the preparation of their ester such as (S)-(?)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide or (R)-(+)-10-acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide. The present invention also provides novel solid state crystalline forms J1, J2, J3, J4 and amorphous form of eslicarbazepine and the process for the preparation thereof. Also, the present invention provides novel solid state crystalline form and amorphous form of eslicarbazepine acetate and the process for the preparation thereof.
    Type: Grant
    Filed: March 6, 2012
    Date of Patent: May 24, 2016
    Assignee: JUBILANT LIFE SCIENCES LIMITED
    Inventors: Sujay Biswas, Shailendra Kumar Dubey, Vikas Bansal, Mukesh Masand, Dharam Vir
  • Patent number: 9234885
    Abstract: Methods and assays for treating a subject with a filovirus infection using an agent that inhibits Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4. Methods for screening for an agent that treats and/or prevents infection of a subject with a filovirus, where the methods comprise determining whether the agent inhibits one or more of Niemann-Pick CI (NPCI), VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41. BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4, wherein an agent that inhibits one or more of NPCI, VPSII, VPSI6, VPSI8, VPS33A, VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is a candidate for treating and/or preventing an infection with a filovirus and wherein an agent that does not inhibit NPCI, VPSII, VPSI6, VPSI8, VPS33A. VPS39, VPS41, BLOCISI, BLOCIS2, GNPTAB, PIKFYVE, ARHGAP23 or FIG4 is not a candidate for treating and/or preventing an infection with a filovirus.
    Type: Grant
    Filed: January 24, 2012
    Date of Patent: January 12, 2016
    Assignees: Albert Einstein College of Medicine, Inc., President and Fellows of Harvard College, Whitehead Institute For Biomedical Research
    Inventors: Kartik Chandran, Sean Whelan, Thijn Brummelkamp, Jan Carette, Matthijs Raaben
  • Patent number: 9221779
    Abstract: Novel serotonin reuptake inhibitor compounds which are designed to exert serotonin uptake inhibitory activity in the peripheral system while being devoid of CNS activity, and a process of preparing same are disclosed. Further disclosed are pharmaceutical compositions containing same and uses thereof in the treatment of medical conditions associated with peripheral serotonin levels and/or activity, and/or platelet aggregation.
    Type: Grant
    Filed: June 21, 2007
    Date of Patent: December 29, 2015
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Moshe Rehavi, David Gurwitz
  • Patent number: 9192613
    Abstract: This method outlines a process which a patient may follow to find a rapid, safe and effective treatment for the common problem of premature ejaculation. The method progresses through three stages including clinical history, diagnostic testing, and treatment. Treatment of primary premature ejaculation includes assessing the condition of the male to establish that the male has primary premature ejaculation as opposed to secondary premature ejaculation and, if the male is diagnosed as having primary premature ejaculation, identifying a treatment protocol that progresses to a safest and most effective methodology in a shortest number of steps.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: November 24, 2015
    Assignee: Sapere IP, LLC
    Inventor: Ramsay Sallis
  • Patent number: 9134297
    Abstract: The present invention relates to anti-cancer therapeutics. In certain aspects, cancers are treated with a combination of an anti-EGFR agent and an agent that increases the activity of the KLF6 tumor suppressor gene and/or an agent that increases activity of the FOXO1 tumor suppressor gene. In a preferred aspect, the anti-EGFR agent erlotinib a tricyclic agent compound, are used in combination to treat non-small cell lung cancer in a patient with primary or acquired drug resistance to erlotinib, and wherein the tricyclic agent is administered in an amount that does not lead to a substantial central nervous system effect. In additional aspects, the invention relates to compositions and kits useful for treating cancers, methods for screening for compounds that enhance the activity of anti-EGFR agent, and methods for determining whether a patient will respond to anti-EGFR therapy.
    Type: Grant
    Filed: January 11, 2012
    Date of Patent: September 15, 2015
    Assignee: Icahn School of Medicine at Mount Sinai
    Inventors: Goutham Narla, Michael Ohlmeyer, Matthew David Galsky
  • Patent number: 9023841
    Abstract: This disclosure provides methods for treating asthma or an associated disorder in a patient in need thereof, by administering to the patient an effective amount of an autophagy inducing agent, thereby treating the asthma or the associated disorder. Disorders that can be treated include, allergic asthma, chronic obstructive pulmonary disease, lung inflammation, respiratory tolerance and a lung infection or disorder.
    Type: Grant
    Filed: August 2, 2012
    Date of Patent: May 5, 2015
    Assignee: University of Southern California
    Inventor: Omid Akbari
  • Publication number: 20150111878
    Abstract: The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 23, 2015
    Inventor: STEVEN HOFFMAN
  • Publication number: 20150098978
    Abstract: A tablet that includes a solid solution of soluble fiber and one or more sugar alcohols, the solid solution having a glass transition temperature of less than 40° C., and one or more additives dispersed in the solid solution such that at least one additive is released from the tablet when the tablet is chewed or dissolved within an oral cavity.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Feng Gao, Diane L. Gee, Phillip M. Hulan, Shuzhong Zhuang, William J. Burke, Gerd Kobal
  • Publication number: 20150098909
    Abstract: A soluble fiber lozenge provided herein includes a body that is partially or wholly receivable in an oral cavity. The body includes a soluble-fiber matrix and one or more additives dispersed in the soluble-fiber matrix. In some cases, a soluble fiber lozenge provided herein includes at least 40 weight percent of soluble fiber. In some cases, soluble fiber in soluble fiber lozenge provided herein can include maltodextrin. The soluble fiber lozenge is adapted to release one or more additives from the body when the body is received within the oral cavity of a consumer and exposed to saliva. A method of making soluble fiber lozenges provided herein includes forming a molten mixture of at least 40 weight percent soluble fiber, one or more additives, and less than 15 weight percent water while maintaining a mixture temperature of less than 200° C. and portioning the molten mixture into a plurality of soluble fiber lozenges. In some cases, the ingredients can be mixed to form the molten mixture in an extruder.
    Type: Application
    Filed: October 3, 2014
    Publication date: April 9, 2015
    Inventors: Feng Gao, Diane L. Gee, Shuzhong Zhuang, Phillip M. Hulan, William J. Burke, Gerd Kobal
  • Publication number: 20150099739
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Application
    Filed: July 29, 2014
    Publication date: April 9, 2015
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards
  • Publication number: 20150099015
    Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.
    Type: Application
    Filed: November 24, 2014
    Publication date: April 9, 2015
    Inventor: Guochuan Emil TSAI
  • Publication number: 20150094301
    Abstract: Controlled-release preparations of oxcarbazepine and derivatives thereof for once-a-day administration are disclosed. The inventive compositions comprise solubility- and/or release enhancing agents to provide tailored drug release profiles, preferably sigmoidal release profiles. Methods of treatment comprising the inventive compositions are also disclosed.
    Type: Application
    Filed: July 29, 2014
    Publication date: April 2, 2015
    Inventors: Padmanabh P. Bhatt, Argaw Kidane, Kevin Edwards